1,210
Participants
Start Date
November 3, 2021
Primary Completion Date
August 6, 2023
Study Completion Date
February 6, 2024
Best Practice Alert
Providers randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF and absence of MRA prescription, notes the patient's current LVEF, and notes the most recent labs, including NT-ProBNP, potassium, and creatinine. Providers will also have access to a link to best available guideline recommended information regarding use of MRAs and a link to both an order set for prescribing an MRA and an alternate order set with option for potassium monitoring should hyperkalemia be a concern. If a patient is hyperkalemic (i.e. K ≥ 5 mEq/L), a link to an order set for prescribing a potassium binder will be provided instead. If a provider feels that the recommended therapy is not indicated for a particular patient, he/she can select an available reason from the list provided within the alert.
Cardiology/Internal Medicine Outpatient Clinics of Yale New Health System, New Haven
Collaborators (1)
Vifor Pharma
INDUSTRY
Relypsa, Inc.
INDUSTRY
Yale University
OTHER